New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—

Capital & Financial Ratios $m

Size
Market Cap 11
Revenue ttm —
Net income ttm —
Free cash flow ttm (89)
Net debt Q (3)
Valuation
P/E —
Forward P/E FY27e —
Price / sales —
Forward P/S FY27e Powerpack
Price / FCF —
Price / book —
Financial health
Current ratio Q 1.2
Debt / equity Q n/m
Interest coverage Q —
Growth
Revenue growth FY27e —
EPS growth FY27e +45.3% (at or above 15%: strong)
EPS growth FY28e 0.0%
EPS growth, 5 yrs e −5.5% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY27e the fiscal year ending in 2027; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Valuation

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — 0 2 2 +209.4% — — — —
Gross margin, % — — — — — — — 100.00 1.08 9.52 (90.5) pt
EBT — — — — — — — (31) (25) (39) n/m
EBT margin, % — — — — — — — (15,994.80) (1,052.43) (2,055.54) +13,939.3 pt
Net income — — — — — — — (31) (25) (39) n/m
Per share, $
Per share, $ Revenue — — — — — — — 0.15 0.34 0.18 +9.7%
Earnings — — — — — — — (24.41) (3.58) (3.65) n/m
Cash flow — — — — — — — (11.70) (3.42) (3.50) n/m
Capex — — — — — — — 0.00 0.28 0.00 n/m
Free cash flow — — — — — — — (11.70) (3.14) (3.50) n/m
Book value — — — — — — — 13.93 4.00 1.48 (67.4%)
Shares, m — — — — — — — 1 7 10 +182.0%
Valuation, ×
Valuation, × P/E — — — — — — — — — — —
P/S — — — — — — — — — — —
P/B — — — — — — — 0.00 0.00 0.00 0.0
EV/Sales — — — — — — — 0.00 0.00 0.00 0.0
EV/FCF — — — — — — — 0.00 0.00 0.03 0.0
Cash, $m
Cash, $m Operating cash flow — — — — — — — (15) (24) (36) n/m
Capex — — — — — — — — 2 — —
Free cash flow — — — — — — — (15) (22) (36) n/m
Balance, $m
Balance, $m Working capital — — — — — — — 3 16 2 (22.9%)
Net debt — — — — — — — (12) (19) (3) n/m
Shareholders’ equity — — — — — — — 18 28 15 (8.1%)
Returns, %
Returns, % ROA — — — — — — — — (48.10) (79.84) (31.7) pt
ROIC — — — — — — — (336.13) (173.45) (195.15) +141.0 pt
ROE — — — — — — — — (108.66) (180.13) (71.5) pt
People
People Employees — — — — — — — 7 14 14 +41.4%
Revenue/emp, $m — — — — — — — 0.03 0.17 0.13 +118.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Jun 2026 · fundamentals updated Nov 2, 2026

Radiopharm Theranostics Limited - Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BCDA BioCardia, Inc. $11.7M — (loss-making) — (loss-making) −93.02% (below 0%: shrinking) n/m −2.93% (below 0%: shrinking) 100.00% (54,966.67%) Compare
PASG Passage Bio, Inc. $11.6M — (loss-making) — — n/m +17.68% (above 0%: growing) 0.00% — Compare
AEON AEON Biopharma, Inc. $11.2M — (loss-making) — — n/m −120.53% (below 0%: shrinking) — — Compare
PBM Psyence Biomedical Ltd. $10.9M 0.1× — — n/m −1,628.07% (below 0%: shrinking) — — Compare
RADX Radiopharm Theranostics Limited - Sponsored ADR $10.6M — — — — — — —
HIND Vyome Holdings, Inc. $10.2M — (loss-making) — (loss-making) +67.63% (above 0%: growing) n/m +63.50% (above 0%: growing) 46.21% (1,760.52%) Compare
LSTA Lisata Therapeutics, Inc. $9.8M — (loss-making) — (loss-making) — n/m −279.44% (below 0%: shrinking) 100.00% (3,080.00%) Compare
BIVI BioVie Inc. $9.8M — (loss-making) — — n/m +3.92% (above 0%: growing) 0.00% 0.00% Compare
LEXX Lexaria Bioscience Corp. $9.5M — (loss-making) — (loss-making) — n/m +53.90% (above 0%: growing) 100.00% (7,259.50%) Compare
Median of peers $10.5M — — — — +0.49% 73.11% (3,080.00%)

All 621 Biotechnology stocks →

Radiopharm Theranostics Limited - Sponsored ADR (RADX) Latest News

What happened

  1. Results Radiopharm Theranostics reported 93.5% patient-level agreement between RAD101 PET/CT and contrast-enhanced MRI in 32 participants.
19 more headlines
All RADX news, as stories →
stockrow.com/RADX · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com